CMS Final Rule Addresses Using 340B Drugs in Medicaid Managed Care

by Admin | April 29, 2016 4:18 pm

April 29, 2016—States must require Medicaid managed care organizations to establish procedures to exclude utilization data for drugs subject to 340B drug discounts from the utilization reports submitted to states for purposes of collecting Medicaid drug rebates, the Centers for Medicare & Medicaid Services says in a new final regulation. States also can opt instead to require covered entities to submit 340B claims data directly to the state or its contractors so the claims can be scrubbed from rebate submissions, CMS said.  

---

You must be registered to read complete articles (it's quick, easy, and 100% free). Click here to register[1].    Already registered? Click here to login[2]. (340B Health members, Drug Discount Monitor subscribers, and 340B Coalition conference attendees: Use your existing username and password.)

Source URL: https://340binformed.org/2016/04/cms-final-rule-addresses-using-340b-drugs-in-medicaid-managed-care/

---